Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 27 October 2016 | By Zachary Brennan
China Food and Drug Administration (CFDA) announced Thursday that its priority review and approval procedure for medical devices will come into force as of 1 January 2017.
The move is part of CFDA’s implementation of reforms to its approval systems for drugs and devices, and to meet the clinical demands of medical devices.
According to the law firm Ropes & Gray, the new policy, first drafted in June, will allow applicants with a Class II device (limited to imported application) or a Class III device (both domestic and imported application) to request a priority review if the device (i) has been enrolled in the National Science and Technology Major Project or National Key Research and Development Plan, or if it can diagnose and treat:
Process for Priority Review
Prior to a device being marketed in China, Class II and Class III devices must go through a technical review process conducted by the Center for Device Evaluation under the CFDA or at the provincial level.
That review assesses whether a device is eligible for priority review, and a decision on the priority review designation will be made before the technical review process begins.
For any application that passes the initial eligibility review, an outside third party may submit an opposition to challenge the result during the public notification period.
For those device applications that receive the priority review designation, companies will be eligible to take advantage of several features, including frequent interactions with the technical review team.
Ropes & Gray also notes that CFDA has already developed two expedited approval processes for devices, including an accelerated approval for devices applicable to emergency public health incidents and a fast track approval for innovative devices.
In addition to the priority reviews, CFDA is also undergoing a major shift in policy on device quality and clinical trials.
Meanwhile, the fast-track scheme for pharmaceuticals is intended to target and prioritize new treatments for cancer, rare diseases, AIDS, tuberculosis and viral hepatitis, as well as those aimed at pediatric and elderly patients.
Tags: China priority reviews for devices, accelerated approval for medical devices
Regulatory Focus newsletters
All the biggest regulatory news and happenings.